Skip to main content

Table 2 Inclusion criteria for HCS transplantation in various autoimmune diseases

From: Immune ablation and stem-cell therapy in autoimmune disease - Clinical experience

Disease/

 

general

 

principles

Criteria

General

Failed best available conventional therapy

 

Progressive disease, poor prognosis (for life or organ)

 

Reasonable quality of life if autoimmune disease activity

 

   were arrested

 

<60 years old

 

Able to withstand HSC transplantation (especially

 

   cyclophosphamide 4 g/m2)

SSc

Diffuse skin disease for <3 years and progressive plus

 

   other organ involvement

 

Modified Rodnan >16 (max 51)

 

Diffuse skin disease for >3 years or limited skin and vital

 

   organ involvement (threatening)

 

Mean PAP <50 mmHg, DLCO >45% predicted

 

LVEF >50% of normal (on echo), >45% MUGA

 

Controlled arrhythmias

 

Hypertension controlled by ACE inhibitors

 

Serum creatinine <1.5 times normal upper limit

RA

Failed: two DMARDS (including methotrexate) + any

 

   combination of DMARDS + anti-TNF regimen

 

Progressive destruction

 

Disease duration 2-10 years

MS

Disease duration ≥ 1 year

 

EDSS between 3.0 and 6.5

 

Disability progression sustained for at least 6 months

 

   during the previous 2 years of:

 

   ≥ 1.5 EDSS points if entry EDSS between 3.0 and 5.0

 

   ≥ 1.0 EDSS point if entry EDSS ≥ 5.5

 

Primary or secondary progressive MS

 

Clinical or MRI activity during the past year

  1. ACE, angiotensin-converting enzyme; DLCO, lung diffusion capacity; DMARD, disease-modifying antirheumatic drug; EDSS, extended disability score system; LVEF, left ventricular ejection fraction; MRI, magnetic resonance imaging; MUGA, multigated image acquisition; PAP, pulmonary artery pressure; TNF, tumour necrosis factor.